Search

Displaying results 4731 - 4740 of 10000 in total
  1. Drug

    PMI-001

    go.drugbank.com/drugs/DB05730
    Experimental

    It is an extract of the roots of an undisclosed perennial shrub which interferes with the production of IL-2 and COX-2 proteins, for the potential treatment of autoimmune diseases, such as rheumatoid arthritis … PMI-001 is a stand-alone, disease-modifying, anti-rheumatic drug (DMARD) being developed by Phytomedics Inc.

  2. Drug

    Methscopolamine bromide

    go.drugbank.com/drugs/DB00462
    Approved

    A muscarinic antagonist used to study binding characteristics of muscarinic cholinergic receptors.

    Synonyms: N-methylhyoscine bromide, N-methylscopolammonium bromide
  3. Drug

    Human Menstrual Blood-derived Stem Cells

    go.drugbank.com/drugs/DB15738
    Investigational

    Because this is a non-invasive way to obtain stem cells, it is simple and easy to obtain the stem cells with an absence of ethical issues that may come from obtaining stem cells of the embryonic kind. … MenSCs are special compared to older methods of adult stem cell extraction such as bone marrow stem cell extraction because MenSC extraction is a non-invasive method.

  4. Drug

    FP0011

    go.drugbank.com/drugs/DB05090
    Experimental

    FP0011 is a small molecule antiglutamatergic compound with symptomatic and disease modifying effects in a variety of neurological disorders (amyotrophic lateral sclerosis and Parkinson's disease). … It acts on the presynaptic regulation of glutamate and shows strong neuroprotective properties.

  5. Drug

    Padimate A

    go.drugbank.com/drugs/DB11229
    ApprovedWithdrawn

    In Europe this chemical was withdrawn in 1989 for unstated reasons and in the US it was never approved for use in sunscreens. … Padimate A is an ester derivative of PABA and an ingredient in some sunscreens.

  6. Drug

    Anecortave acetate

    go.drugbank.com/drugs/DB05288
    Investigational

    Anecortave acetate (Retaane) is an analog of cortisol acetate; among the modifications to the steroid are the removal of the 11ß hydroxyl OH group and an addition of a 21-acetate group. … As a result of these modifications, anecortave acetate lacks the typical antiinflammatory and immunosuppressive properties of glucocorticoids.Alcon Inc. is developing and marketing Retaane.

  7. Drug

    Drinabant

    go.drugbank.com/drugs/DB05750
    Investigational

    It is currently developed in obesity and its associated comorbidities. AVE-1625 is also being developed for the treatment of Alzheimer disease. … AVE-1625 is an oral selective and potent antagonist of cannabinoid 1 (CB1) receptors having the same mechanism of action as rimonabant.

  8. Drug

    BOS172722

    go.drugbank.com/drugs/DB15498
    Investigational

    The key role of Mps1 in the growth of cancer cells renders it an appealing target for cancer treatment, as its inhibition could lead to favorable effects. … [A187120] An in vivo study combined BOS172722 with [Paclitaxel] for the treatment of triple hormone receptor negative breast cancer, and demonstrated promising synergistic effects.[A187123]

  9. Drug

    Pilaralisib

    go.drugbank.com/drugs/DB11772
    Investigational

    Pilaralisib has been used in trials studying the treatment of Cancer, Lymphoma, Solid Tumors, Glioblastoma, and Breast Cancer, among others. … Pilaralisib is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K).

  10. Drug

    GT 389-255

    go.drugbank.com/drugs/DB05894
    Experimental

    MAD) Phase I trials. … It is expected to block fat absorption with fewer side effects than currently marketed lipase inhibitors.